Order results by:
| Issue | Title | |
| Vol 11, No 3 (2018) | Pharmacoeconomic analysis of using belimumab for the treatment of systemic lupus erythematosus | Abstract similar documents |
| A. G. Tolkushin, N. L. Pogudina | ||
| "... in patient survival. The total costs for belimumab vs standard therapy approximated 8.84 million rubles vs 17 ..." | ||
| Vol 7, No 3 (2014) | ASSESSMENT OF NECESSARY FINANCIAL EXPENSES ON THE DRUG SUPPLY OF THE PATIENTS WITH ORPHAN DISEASES IN THE RUSSIAN FEDERATION | Abstract similar documents |
| M. V. Sura, K. V. Gerasimova, V. V. Omelyanovskiy, M. V. Avksentyeva | ||
| "... orphan diseases were 15.73 bln rubles per year (6.36 bln rubles for children and 9.37 bln rubles ..." | ||
| Vol 12, No 2 (2019) | Comparative modeling of socio-economic burden among smokers, nonsmokers and former smokers | Abstract similar documents |
| E. V. Radchenko, A. S. Kolbin | ||
| "... disability) was 510.6 billion rubles. The difference between the smokers and the equal-sized non-smoking ..." | ||
| Vol 9, No 3 (2016) | METHOD «COST-EFFECTIVENESS» IN EVALUETION OF ATIBIOTIC TREATMENT OF ACYTR OBSTRUCTIVE BRONCHITIS IN CHILDREN IN HOSPITAL | Abstract similar documents |
| O. V. Zhukova, S. V. Kononova | ||
| "... for Sumamed (Teva), and it amounted to 39 367.50 rubles. Sumamed was characterized by the highest clinical ..." | ||
| Vol 12, No 4 (2019) | Pharmacoeconomic analysis of using biological agents for uncontrolled moderate-to-severe atopic asthma in the Russian Federation | Abstract similar documents |
| S. K. Zyryanov, I. N. Diyakov, S. N. Avdeev | ||
| "... the competitors. To prevent asthma exacerbations by omalizumab requires 463 805 rubles, which is 24.80% less than ..." | ||
| Vol 12, No 2 (2019) | Pharmacoeconomic analysis of ceftazidime+avibactam (Zavicefta®) in the treatment of sepsis caused by carbapenem-resistant enterobacteria | Abstract similar documents |
| S. V. Nedogoda, A. S. Salasyuk, I. N. Barykina, V. O. Smirnova | ||
| "... with ceftazidime + avibactam amounted to 228.3 thousand rubles, which was lower than the cost of using ..." | ||
| Vol 10, No 2 (2017) | CLINICAL AND ECONOMIC EVALUATION OF CHRONIC DISEASE TREATMENT: A DISCREPANCY BETWEEN THE TRADITIONAL PHARMACOECONOMIC AND SOCIO-ECONOMIC ANALYSES | Abstract similar documents |
| O. V. Zhukova, S. V. Kononova | ||
| "... in medical costs from 873.00 rubles to 1515.39 rubles, and to a decrease in the average number ..." | ||
| Vol 10, No 1 (2017) | EVALUATION OF DRUG THERAPY IN PROGRESSING DIFFERENTIATED THYROID CANCER REFRACTORY TO RADIOACTIVE IODINE IN PATIENTS RESIDING IN THE RUSSIAN FEDERATION : PHARMACOECONOMIC ASPECTS | Abstract similar documents |
| M. Yu. Frolov, V. A. Rogov | ||
| "... with sorafenib or lenvatinib was 7 285 716.92 rubles or 3 368 077.62 rubles, respectively. ..." | ||
| Vol 8, No 4 (2015) | PLANNING OF EXTENT AND FINANCIAL EXPENSES FOR DELIVERY OF HEALTH CARE IN HOSPITALS AT THE FEDERAL AND REGIONAL LEVELS | Abstract similar documents |
| M. V. Sura | ||
| "... per year; the norm of financial expenses was 63 743,8 rubles and 22 233,1 rubles per one case ..." | ||
| Vol 9, No 2 (2016) | METASTATIC COLORECTAL TREATMENT COSTS OF USING TARGETED DRUGS IN SECOND AND FURTHER LINES THERAPY | Abstract similar documents |
| N. A. Avxentyev, E. V. Derkach, E. A. Pyadushkina, M. D. Ter-Ovanesov | ||
| "... per patient medication costs of using regorafenib are 255,000 rubles, which is 104,000 rubles less ..." | ||
| Vol 11, No 3 (2018) | Determination of a willingness-to-pay threshold and decision-making in financing the healthcare technologies | Abstract similar documents |
| T. S. Teptsova, T. P. Bezdenezhnyh, V. K. Fedyaeva, N. Z Musina, G. R. Hachatryan, V. V. Tarasov | ||
| "... ,878.21 rubles, and the cost of one additionally saved QALY – 365,060.31 rubles. Conclusion. The WTPT ..." | ||
| Vol 10, No 2 (2017) | COST-EFFECTIVENESS OF VILANEROL / UMECLIDINIUM VERSUS TIOTROPIUM IN SEVERE AND VERY SEVERE COPD | Abstract similar documents |
| E. G. Kosolapov, F. S. Kochenkov, N. L. Pogudina, D. V. Blinov | ||
| "... groups amounted to 32,753 rubles and 37,641 rubles, respectively. Thus, the savings of using the combined ..." | ||
| Vol 8, No 2 (2015) | PHARMACOECONOMIC STUDIES TREATMENT OF PATIENTS WITH INJURIES IN THE DEPARTMENT OF ANESTHESIOLOGY AND RESUSCITATION WITH METHODS ANALYSIS THE COST OF ILLNESS | Abstract similar documents |
| Anton Alexandrovich Kasatkin | ||
| "... with the severity of the injury 31 points and made 11 000 and 5600 rubles. respectively. The cost of treating ..." | ||
| Vol 9, No 1 (2016) | PHARMACOECONOMIC STUDY OF LENVIMA (LENVATINIB) IN ADVANCED PROGRESSIVE RADIO IODINE REFRACTORY DIFFERENTIATED THYROID CANCER IN THE RUSSIAN FEDERATION | Abstract similar documents |
| M. Yu. Frolov, V. A. Rogov | ||
| "... at the same time constitute 5 213 900 000 rub. (670.5 to 1184.3 million rubles per year). Calculated unit ..." | ||
| Vol 10, No 3 (2017) | Evaluation of economic damage from multiple sclerosis in the city of Ufa, Russia | Abstract similar documents |
| E. V. Ivanova, K. Z. Bachtiyarova | ||
| "... 428,222,026.35 rubles per year, mostly due to direct medical costs; of those, almost 50% is spent ..." | ||
| Vol 10, No 2 (2017) | COST-MINIMIZATION OF VILANTEROL / UMECLIDINIUM VERSUS OLODATEROL / TIOTROPIUM IN THE BASIC THERAPY OF SEVERE AND VERY SEVERE COPD | Abstract similar documents |
| E. G. Kosolapov, F. S. Kochenkov, N. L. Pogudina, D. V. Blinov, N. L. Bondarenko, A. V. Karaulov | ||
| "... / umeclidinum bromide and with olodaterol / tiotropium bromide were 27,541 and 36,120 rubles, respectively ..." | ||
| Vol 8, No 4 (2015) | THE COST OF NUTRITION ALTERNATIVES FOR PREMATURE INFANTS IN RUSSIA | Abstract similar documents |
| K. V. Gerasimova, M. V. Avxentyeva, I. A. Belyaeva | ||
| "... .14 rubles, respectively). The cost per averted case of NE was 21 115 rubles within 35 days that is less than ..." | ||
| Vol 8, No 4 (2015) | CLINICAL AND ECONOMIC EVALUATION OF THROMBOPOIETIN RECEPTOR AGONISTS IN THE TREATMENT OF CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA IN ADULTS | Abstract similar documents |
| E. A. Pyadushkina, M. Yu. Frolov, M. V. Avksentyeva | ||
| "... of one patient annual therapy by 2.68 mln. rubles. Budget impact analysis evidences that Eltrombopag ..." | ||
| Vol 9, No 4 (2016) | THE COSTS OF REGIONAL ANESTHESIA WITH THE USE OF LEVOBUPIVACAINE, RACEMIC BUPIVACAINE AND ROPIVACAINE | Abstract similar documents |
| G. E. Ulrikh, A. V. Rudakova | ||
| "... бупивакаину левовращающий изомер ропивакаин. Целью работы являлась оценка затрат на анестезию ..." | ||
| Vol 5, No 3 (2012) | CLINICAL AND ECONOMIC BENEFITS OF HUMAN INSULIN ANALOGUESUSE | Abstract similar documents |
| E. E. Arinina, M. A. Rashyd | ||
| "... ®) were 21774 rubles per patient/year, while the cost of an averted severe hypoglycemia was 24728 rubles ..." | ||
| Vol 6, No 4 (2013) | Pharmacoeconomic analysis of fluid therapy in the treatment of patients with peritonitis | Abstract similar documents |
| R. I. Yagudina, M. M. Murashko | ||
| "... пациентов использованы для оценки эффективности. Коэффициенты «затраты-эффективность» составили 440 759 руб ..." | ||
| Vol 12, No 1 (2019) | Economic consequences of healthcare optimization for IBD patients in the Republic of Tatarstan | Abstract similar documents |
| T. P. Bezdenezhnykh, D. V. Fedyaev, G. R. Khachatryan, G. G. Arutyunov, K. V. Gerasimova | ||
| "... by 120 million rubles over 5 years. The sensitivity analysis shows the results are robust ..." | ||
| Vol 9, No 2 (2016) | PHARMACOECONOMIC ANALYSIS OF VESOMNI (SOLIFENACIN AND CONTROLLED RELEASE TAMSULOSIN) TREATMENT OF STORAGE SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA | Abstract similar documents |
| N. A. Avxentyev, M. Yu. Frolov | ||
| "... combined drug is cost saving alternative that annually requires 22,000 rubles per patient, which is 2 ..." | ||
| Vol 5, No 3 (2012) | COST-UTILITY ANALYSIS PATIENTS WITH LOW BACK PAIN AFTER TREATMENT INTRAOSSEOUS BLOCKADES | Abstract similar documents |
| M. V. Yakovlev, A. U. Kulikov, E. L. Sokov, I. E. Kornilova | ||
| "... , физиотерапия). Анализировались прямые затраты в течение 12 месяцев наблюдения пациентов. Показатели качества ..." | ||
| Vol 8, No 2 (2015) | CLINICAL AND ECONOMIC ANALYSIS OF THE USE OF DIFFERENT TYPES OF SYSTEMS OF VENOUS ACCESS IN THE TREATMENT OF CHILDREN WITH CANCER | Abstract similar documents |
| Maksim Yur'evich Rykov, Vladimir Georgievich Polyakov | ||
| "... of treatment five subclavian catheters necessary to spend 227.25 mln. rubles. And the implantations of venous ..." | ||
| Vol 6, No 3 (2013) | PHARMACOECONOMIC ANALYSIS OF NEUROPROTECTIVE DRUGS IN THE TREATMENT OF ACUTE DISORDERS OF CEREBRAL CIRCULATION | Abstract similar documents |
| A. Yu. Kulikov, I. Yu. Zinchuk | ||
| "... Це- раксон в фармакотерапии ОНМК, обусловленное снижением суммы прямых затрат на 22 311 руб. и 21 345 ..." | ||
| Vol 11, No 2 (2018) | Clinical and economic efficiency of the loop ileostomy closure by various methods | Abstract similar documents |
| A. V. Veselov, S. I. Achkasov, O. I. Sushkov, A. I. Moskalev, I. S. Lantsov | ||
| "... ,704.90 rubles. and 145,473.70 rubles, respectively, while in group 3, the cost was higher – 167,443,60 rubles (p ..." | ||
| Vol 10, No 1 (2017) | PERAMPANEL EFFECTIVENESS IN THE TREATMENT OF REFRACTERY PARTIAL ONSET EPILEPSY WITH OR WITHOUT SECONDARY GENERALIZATION: PHARMACOECONOMIC ANALYSIS FOR THE RUSSIAN FEDERATION HEALTH CARE SYSTEM | Abstract similar documents |
| N. K. Mazina, I. V. Sheshunov, P. V. Мazin, Yu. V. Kislitsin, E. M. Markova | ||
| "... than 40% (up to 4-7 bln. rubles) annually until 2020. ..." | ||
| Vol 12, No 4 (2019) | Optimization of drug supply for patients with malignant neoplasms in a region of the Russian Federation | Abstract similar documents |
| A. V. Nikitina, F. V. Gorkavenko, Y. S. Saybel, M. V. Avxentyeva, M. S. Sura, D. V. Fedyaev | ||
| "... the costs of drugs for solid tumors at the 352.2 million rubles for 5 years (baseline scenario), 69 ..." | ||
| Vol 10, No 3 (2017) | Initiation and intensification of insulin therapy in patients with type 2 diabetes mellitus: a budget impact analysis | Abstract similar documents |
| E. V. Biryukova, V. I. Ignat’eva | ||
| "... insulin for the model population of 1,000 patients was 22.5 million rubles. If the use of ready-made ..." | ||
| Vol 5, No 3 (2012) | PHARMACOECONOMIC EVALUATION OF TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS ON DIALYSIS WITH CINACALCET | Abstract similar documents |
| R. I. Yagudina, V. G. Serpik | ||
| "... was 20,709 rubles. (Taking into account the costs of dialysis treatments), and for standard therapy - 110 ..." | ||
| Vol 5, No 1 (2012) | PHA RMA COE CONOMI CAL EVALUATION OF MULTIPLE MYELOMA TREATMENT WITH REVLIMID (LENALIDOMIDE ) IN THE RUSSIAN FEDE RATION | Abstract similar documents |
| R. Yagudina, A. Kulikov, B. Misikova | ||
| "... Федерации. Результаты: Коэффициенты «затраты-эффективность» при использовании Ревлимида во второй линии ..." | ||
| Vol 11, No 2 (2018) | Pharmacoeconomic analysis of treatment with nilotinib as the second line therapy in patients with chronic myeloid leukemia | Abstract similar documents |
| N. A. Avxentyev, M. Yu. Frolov, A. S. Makarov | ||
| "... approval process. Results. The average medical cost (per year) for nilotinib (1 683 thousand rubles or US ..." | ||
| Vol 6, No 4 (2013) | Фармакоэкономический анализ использования лираглутида в составе комбинированной терапии в лечении сахарного диабета 2-го типа | Abstract similar documents |
| A. Yu. Kulikov, I. V. Novikov | ||
| "... , моделирование. Метод фармакоэкономического анализа – «затраты-полезность». Горизонт моделирования – 10 лет ..." | ||
| Vol 12, No 3 (2019) | Pharmacoepidemiological analysis of antimicrobial therapy for burn injury in the hospital settings | Abstract similar documents |
| O. V. Zhukova, E. S. Nekaeva, E. S. Khoroshavina, E. A. Kozlova, Yu. A. Dudukina, I. Yu. Arefyev | ||
| "... in segments DU10% and DU90% amounted to 1976.80 rubles and 1282.58 rubles, respectively. In group A, 80 ..." | ||
| Vol 7, No 3 (2014) | PHARMACOECONOMIC ANALYSIS OF THE USE OF OXALIPLATIN CHEMOTHERAPY FOR COLORECTAL CANCER.REAL (ACTUAL) CLINICAL PRACTICE DATA | Abstract similar documents |
| A. V. Pavlysh, A. S. Kolbin, A. R. Kasimova | ||
| "... .2%. Middle cover price of case report was 252,294 rubles. In average oxaliplatin therapy was effective in 83 ..." | ||
| Vol 8, No 1 (2015) | SOCIAL AND ECONOMIC BURDEN OF FIVE NATURAL FOCAL INFECTIONS IN THE RUSSIAN FEDERATION | Abstract similar documents |
| A. E. Platonov, N. A. Avksentyev, M. V. Avksentyeva, E. V. Derkach, O. V. Platonova, A. V. Titkov, N. M. Kolyasnikova | ||
| "... with vector-borne infectious diseases comprised 909 million rubles in prices of 2011; most of the value ..." | ||
| Vol 10, No 2 (2017) | COMPARATIVE COST-MINIMIZATION AND BUDGET-IMPACT ANALYSIS OF FIXED-DOSE INHALED CORTICOSTEROID / LONG-ACTING BETAAGONIST COMBINATIONS IN THE TREATMENT OF ASTHMA | Abstract similar documents |
| N. L. Pogudina, E. G. Kosolapov, F. S. Kochenkov, A. V. Karaulov, N. L. Bondarenko, D. V. Blinov | ||
| "... затрат и анализ влияния на бюджет. Результаты. Сумма прямых медицинских затрат при использовании ..." | ||
| Vol 6, No 4 (2013) | Pharmacoeconomical assessment of сerebrolysin in the treatment of the acute disturbances of cerebral circulation | Abstract similar documents |
| A. Yu. Kulikov, L. A. Komarov | ||
| "... церебролизина для лечения ОНМК по ишемическому типу позволяет сэкономить примерно 1,47 млрд руб. в год в расчете ..." | ||
| Vol 6, No 2 (2013) | FIRST RUSSIAN TYPE 2 DIABETES MELLITUS SIMULATION MODEL WITH DISCREET EVENTS MODELING. HEALTH-ECONOMIC ANALYSIS | Abstract similar documents |
| A. S. Kolbin, O. K. Khmelnitskiy, A. A. Kurylev, Yu. E. Balykina, M. A. Proskurin, E. P. Kolpak, M. V. Bure | ||
| "... изменение биохимических параметров (HbA1c, липидограммы, артериального давления). Проведен анализ «затраты ..." | ||
| Vol 10, No 1 (2017) | BIOLOGICAL THERAPY IN ADULT PATIENTS WITH ULCERATIVE COLITIS AND CROHN’S DISEASE: BUDGET IMPACT ANALYSIS | Abstract similar documents |
| E. A. Pyadushkina | ||
| "... % and 7% for the first, second and third year is expected to result in cost savings of 26.4 million rubles ..." | ||
| Vol 8, No 4 (2015) | HEALTHCARE SPENDING EFFICIENCY IN RUSSIAN REGIONS | Abstract similar documents |
| N. A. Avxentyev, V. M. Baydin, O. A. Zarubina, N. N. Sisigina, S. A. Kulkova | ||
| "... healthcare spending inefficient, which equals to real 269-435 billion rubles of inefficient spending annually. ..." | ||
| Vol 12, No 4 (2019) | Pharmacoeconomic analysis of using cyclin-dependent kinase 4 and 6 inhibitors in the first line treatment of HR-positive HER2-negative advanced breast cancer | Abstract similar documents |
| N. A. Avxentyev, E. V. Lubennikova, M. Yu. Frolov | ||
| "... качестве метода клинико-экономического исследования была выбрана «минимизация затрат», так как согласно ..." | ||
| Vol 10, No 2 (2017) | ECONOMIC ASSESSMENT OF THE EFFECTIVENESS AND SAFETY OF THE COMMONLY PRACTICED PERIOPERATIVE ANTIBIOTIC PROPHYLAXIS (BASED ON AN EARLIER EPIDEMIOLOGICAL SURVEY OF MULTIDISCIPLINARY HOSPITALS) | Abstract similar documents |
| Yu. M. Gomon, A. S. Kolbin, S. V. Sidorenko, A. M. Kuzhel’, A. V. Repina, Yu. V. Lobzin, Yu. E. Balykina | ||
| "... (4913,67 руб. и 17837,71 руб., соответственно). Анализ «затраты-эффективность» показал, что стратегия ..." | ||
| Vol 9, No 3 (2016) | CLINICAL AND ECONOMIC EVALUATION OF LACOSAMIDE IN PATIENTS WITH PARTIAL EPILEPSY | Abstract similar documents |
| E. A. Pyadushkina, M. Yu. Frolov | ||
| "... .64, 2.65, 4.74 million rubles in the first, second and third year respectively. Scenario 3 ..." | ||
| Vol 8, No 2 (2015) | ASSESSMENT OF ECONOMIC EFFICIENCY OF APPLICATION OF RALTEGRAVIR BY PATIENTS WITHOUT EXPERIENCE OF TYPE 1 HIV INFECTION THERAPY IN RUSSIA | Abstract similar documents |
| Elamin H. Elbasha, Elena Aleksandrovna Pyadushkina, Maria Vladimirovna Avxentyeva, Alexander Gennadievich Tolkushin, Maxim Yurievich Frolov | ||
| "... ) per a year of saved life with consideration of its quality comprised 1,097,078 rubles without ..." | ||
| Vol 5, No 2 (2012) | PHARMACOECONOMIC STUDY OF PRIMARY OPEN-ANGLE GLAUCOMA TREATMENT WITH COMBINATIONS OF PROSTAGLANDIN ANALOGUES AND BETA-BLOCKERS | Abstract similar documents |
| A. Yu. Kulikov, V. G. Serpikov | ||
| "... использованием методов анализа «влияния на бюджет» и анализа «затраты эффективность» получены следующие ..." | ||
| Vol 6, No 1 (2013) | PHARMACOECONOMIC STUDY OF SKIN TESTS IN THE DIAGNOSTICS OF TUBERCULOSIS INFECTION | Abstract similar documents |
| R. I. Yagudina, I. Yu. Zinchuk | ||
| "... применения (2ТЕППД-Л)) в диагностике туберкулезной инфекции у детей и подростков методом «затраты ..." | ||
| Vol 6, No 4 (2013) | Pharmacoeconomic analysis of Anti-inhibitor coagulant complex (AICC) in the treatment of inhibitor hemophilia | Abstract similar documents |
| R. I. Yagudina, I. Yu. Zinchuk | ||
| "... пациентов, чувствительных к данному лечению. В результате анализа прямых и непрямых затрат было установлено ..." | ||
| Vol 7, No 1 (2014) | ABC END VEN ANALYSYS OF COSTS FOR MEDICINE SAND MEDICAL TREATMENT COSTS PATIENT | Abstract similar documents |
| M. A. Shapovalova, L. R. Koretskaya | ||
| 1 - 50 of 125 Items | 1 2 3 > >> | |
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
